Ernexa Therapeutics Inc. Balance Sheet
ERNA|13 years of annual SEC 10-K data (FY2011-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 13 fiscal years. All figures from audited SEC 10-K filings.
Ernexa Therapeutics Inc. had $6M in total assets and $2M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | - | - | $7.6M | - | $3.2M | $2.5M | $5.7M | $3.2M | $7.2M | $5.5M | $2.7M | $1.4M | $3.9M |
| Accounts Receivable | - | - | - | $116.0K | $1.2M | $1.1M | $714.0K | $928.0K | $919.0K | $2.2M | $641.0K | $610.0K | $750.0K |
| Current Assets | $3.1M | $2.4M | $9.6M | $1.7M | $6.1M | $6.8M | $9.6M | $10.7M | $9.1M | $14.9M | $7.9M | $4.2M | $2.8M |
| PP&E (Net) | $94.0K | $85.0K | $493.0K | $502.0K | $2.8M | $4.7M | $3.7M | $3.1M | $3.9M | $3.4M | $3.2M | $3.8M | $4.3M |
| Goodwill | $2.0M | $2.0M | $2.0M | - | $696.0K | $667.0K | $1.0M | $937.0K | $909.0K | $1.1M | $1.2M | $1.3M | $1.2M |
| Total Assets | $5.8M | $5.3M | $49.1M | $3.7M | $14.1M | $14.9M | $16.6M | $16.7M | $16.4M | $22.3M | $15.5M | $12.7M | $11.6M |
| Current Liabilities | $3.1M | $2.9M | $6.6M | $2.4M | $6.1M | $4.0M | $10.7M | $6.6M | $5.1M | $7.1M | $3.6M | $3.4M | $3.9M |
| Shareholders' Equity | $1.7M | $2.2M | $12.1M | $5.1M | $6.9M | $5.5M | $4.1M | $3.8M | $10.9M | $9.2M | $7.9M | $6.3M | $6.3M |